LyseNTech completed MTA and CDA with Y-Biologics
관리자 / 2020-04-27
Sep 10, 2019
LyseNTech completed MTA and CDA with Y-Biologics to develop advanced anticancer phage technology.
Y-Biologics is a Korean biotech company focusing on the discovery & development of novel antibody therapeutics based on its human antibody library and Bi-specific antibody platform technology.